COMPUTERIZED-TOMOGRAPHY IN NEWLY-DIAGNOSED SCHIZOPHRENIA AND SCHIZOPHRENIFORM DISORDER - A CONTROLLED BLIND-STUDY

被引:29
|
作者
RUBIN, P
KARLE, A
MOLLERMADSEN, S
HERTEL, C
POVLSEN, UJ
NORING, U
HEMMINGSEN, R
机构
[1] UNIV COPENHAGEN,BISPEBJERG HOSP,DEPT PSYCHIAT,DK-1168 COPENHAGEN,DENMARK
[2] UNIV COPENHAGEN,BISPEBJERG HOSP,DEPT RADIOL,NEURORADIOL SECT,DK-1168 COPENHAGEN,DENMARK
[3] UNIV COPENHAGEN,FREDERIKSBERG HOSP,DEPT PSYCHIAT,DK-1168 COPENHAGEN,DENMARK
[4] UNIV COPENHAGEN,RIGSHOSP,DEPT PSYCHIAT,DK-2100 COPENHAGEN,DENMARK
[5] UNIV COPENHAGEN,KUMMUNEHOSP,DEPT PSYCHIAT,DK-1168 COPENHAGEN,DENMARK
关键词
D O I
10.1192/bjp.163.5.604
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Patients with newly diagnosed schizophrenia (n = 27) or schizophreniform disorder (n = 22) and 24 healthy volunteers were investigated by CT scan, the investigators being blind to subject status. The patients had never received medication or had been treated only briefly with neuroleptics. The patients had significantly smaller brain volume and brain length than the controls. The patients had greater sulcal enlargement in the case of both Sylvian and interhemispheric fissures and surface sulci in the frontal and parietal regions. The sulcal enlargement was more pronounced in male patients and on the left hemisphere. The study revealed no enlargement of the lateral ventricles and only a trend towards enlargement of the third ventricle in the patients. The findings were not explained by substance abuse or level of education.
引用
收藏
页码:604 / 612
页数:9
相关论文
共 50 条
  • [21] A prospective study to evaluate the value of Positron Emission Computerized Tomography (PET CT) in the primary management of patients with newly diagnosed rectal cancer
    Vuong, T.
    Lisbona, R.
    Artho, G.
    Waschke, K.
    Richard, C.
    Stein, B.
    Charlebois, P.
    Lougnarath, R.
    Portelance, L.
    Reinhold, C.
    RADIOTHERAPY AND ONCOLOGY, 2006, 81 : S77 - S77
  • [22] Parenteral Vitamin D in newly diagnosed Coeliac Disese - Preliminary analysis of double blind placebo controlled study.
    Fickling, WE
    Gupta, R
    Speden, D
    Bhalla, AK
    Ring, FJ
    Robertson, DA
    GASTROENTEROLOGY, 2001, 120 (05) : A394 - A394
  • [23] DOUBLE-BLIND, FIXED-DOSE COMPARISON STUDY OF GABAPENTIN (GBP NEURONTIN(R)) AND CARBAMAZEPINE (CBZ) MONOTHERAPY IN PATIENTS WITH NEWLY-DIAGNOSED PARTIAL EPILEPSY
    ANBUT, H
    GREINER, MJ
    MURRAY, GH
    EPILEPSIA, 1995, 36 : 341 - 341
  • [24] Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: A randomized, double-blind, flexible-dose, multicenter study
    Perkins, Diana O.
    Gu, Hongbin
    Weiden, Peter J.
    McEvoy, Joseph P.
    Hamer, Robert M.
    Lieberman, Jeffrey A.
    JOURNAL OF CLINICAL PSYCHIATRY, 2008, 69 (01) : 106 - 113
  • [25] ADJUNCTIVE TREATMENT WITH NALTREXONE IN PATIENTS WITH SCHIZOPHRENIA AND SUBSTANCE USE DISORDER: A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    Berman, J.
    Savu, R.
    Berman, I.
    EUROPEAN PSYCHIATRY, 2010, 25
  • [26] Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis - A double-blind, placebo-controlled multicenter study
    Pietinalho, A
    Tukiainen, P
    Haahtela, T
    Persson, T
    Selroos, O
    CHEST, 1999, 116 (02) : 424 - 431
  • [27] Supplementation of N-acetylcysteine as an adjuvant in treatment of newly diagnosed pulmonary tuberculosis patients: A prospective, randomized double blind, placebo controlled study
    Nagrale, Dinesh
    Mahakalkar, Sunil
    Gaur, Sanjay
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [28] Osteoporosis and low bone mass among schizophrenia and bipolar disorder: A cross-sectional study with newly diagnosed, drug-naïve subjects
    Li, Sujuan
    Chen, Xiaoqin
    Qiu, Yan
    Teng, Ziwei
    Xu, Xuelei
    Tang, Hui
    Xiang, Hui
    Wang, Bolun
    Chen, Jindong
    Yuan, Hui
    Wu, Haishan
    JOURNAL OF AFFECTIVE DISORDERS, 2024, 348 : 297 - 304
  • [29] Antismoking and potential antipsychotic effects of varenicline in subjects with schizophrenia or schizoaffective disorder: A double-blind placebo and bupropion-controlled study
    Fatemi, S. Hossein
    Yousefi, Mahtab K.
    Kneeland, Rachel E.
    Liesch, Stephanie B.
    Folsom, Timothy D.
    Thuras, Paul D.
    SCHIZOPHRENIA RESEARCH, 2013, 146 (1-3) : 376 - 378
  • [30] A Double-Blind Placebo-Controlled Study of Exenatide for the Treatment of Weight Gain Associated with Olanzapine in Overweight or Obese Adults with Bipolar Disorder, Major Depressive Disorder, Schizophrenia or Schizoaffective Disorder
    Patino, Luis R.
    Rummelhoff, Emily R.
    Blom, T.
    Welge, J.
    Schroeck, Debra
    Adler, Caleb M.
    Strawn, Jeffrey
    Strakowski, Stephen M.
    Moeller, D.
    DelBello, Melissa
    BIOLOGICAL PSYCHIATRY, 2015, 77 (09) : 132S - 132S